|Videos|November 6, 2020

Recent Developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew J. Frigault, MD, reviews the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma and real-world data supporting it's use.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Latest CME